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Introduction
A cell needs to overcome a number of failsafe mechanisms in
order to become cancerous (Hahn and Weinberg, 2002). The
cell must evade apoptosis and senescence programs to survive
the withdrawal of the proper growth factors and nutrients
(Schmitt, 2003); it must override DNA damage checkpoints and
continue proliferating to propagate existing mutations and
acquire new mutations (Malumbres and Barbacid, 2001); and it
must maintain a high growth rate to keep up with the demands
of rapid cell division (Ruggero and Pandolfi, 2003).
Phosphoinositide 3-kinase (PI3K) is a major signaling com-
ponent downstream of growth factor receptor tyrosine kinases
(RTKs) (Cantley, 2002). PI3K catalyzes the production of the
lipid second messenger phosphatidylinositol-3,4,5-triphosphate
(PIP3) at the cell membrane. PIP3 in turn contributes to the
recruitment and activation of a wide range of downstream tar-
gets, including the serine-threonine protein kinase Akt (also
known as protein kinase B). The PI3K-Akt signaling pathway
regulates many normal cellular processes including cell prolifer-
ation, survival, growth, and motility—processes that are critical
for tumorigenesis. Indeed, The role of this pathway in oncogen-
esis has been extensively investigated and altered expression
or mutation of many components of this pathway have been
implicated in human cancer (Vivanco and Sawyers, 2002).
Although both growth factor RTKs and G protein-coupled
receptors can activate PI3K signaling, the involvement of the
latter in cancer is less clear. Here we will limit the scope of our
discussion only to the PI3K-Akt pathway downstream of growth
factor RTKs. The molecular pathways downstream of PI3K and
Akt have been reviewed in detail recently (Cantley, 2002;
Vivanco and Sawyers, 2002). Therefore, we below highlight the
contribution of this pathway to the development of cancer and
focus on the promising approaches toward targeting this path-
way for cancer therapeutics.
Cellular functions of the PI3K-Akt pathway and its
dysregulation in human cancer
Growth factor RTKs engage the class-Ia PI3K, which is a het-
erodimer comprised of the p85 regulatory and p110 catalytic
subunits (Cantley, 2002). Specific phospho-tyrosine residues on
the activated receptor or on associated adaptor proteins bind
the Src-homology 2 (SH2) domains of p85 and recruit the
enzyme to the membrane. The small GTPase Ras can also
recruit and activate PI3K through direct binding to p110. At the
membrane, PI3K phosphorylates phosphatidylinositol-4,5-bis-
phosphate (PIP2) at the 3′ position on its inositol ring and con-
verts PIP2 to PIP3. Subsequently, PIP3 recruits other
downstream molecules—particularly the serine-threonine
kinases Akt and PDK1—via binding to their pleckstrin-
homology (PH) domains. At the membrane, Akt is partially acti-
vated through phosphorylation at threonine 308 in its activation
loop by PDK1. Additional phosphorylation at serine 473 in the C
terminus of Akt results in its full activation. Akt in turn regulates
a wide range of target proteins that control cell proliferation, sur-
vival, growth, and other processes (Figure 1).The levels of PIP3
in the cell are strictly regulated and several lipid phosphatases
act to rapidly remove it. Of particular interest is the 3′ phos-
phatase PTEN, which converts PIP3 back to PIP2 and thus
shuts off PI3K signaling (Cantley and Neel, 1999).
Aberrant activation of the PI3K-Akt pathway has been wide-
ly implicated in many cancers. PI3K was first identified as an
enzymatic activity associated with the Rous sarcoma pp60v-src
protein and the polyoma middle T antigen that is essential for
the transforming activity of these oncogenes (Sugimoto et al.,
1984; Whitman et al., 1985, 1988), and Akt was also found to be
a viral oncogene (Bellacosa et al., 1991). Gene amplification of
p110 occurs in some cases of human ovarian cancer, and
amplification of Akt is found in ovarian, breast, and colon can-
cer. In addition, activating mutations in p85 have been identified
in ovarian and colon cancer (Vivanco and Sawyers, 2002). Most
striking is the discovery of PTEN being a major tumor suppres-
sor in humans (Li et al., 1997; Steck et al., 1997). Germline
mutation of PTEN results in autosomal dominant cancer syn-
dromes such as Cowden’s disease. Furthermore, loss-of-func-
tion mutations in the PTEN gene are extremely common among
sporadic glioblastomas, melanomas, prostate cancers, and
endometrial carcinomas, and a significant percentage of breast
tumors, lung cancers, and lymphomas also bear PTEN muta-
tions (reviewed in Cantley and Neel, 1999). Hyperactivation of
the PI3K-Akt pathway is therefore often genetically selected
during tumorigenesis, and the normal cellular functions regulat-
ed by this pathway are recruited to promote proliferation and
survival of cancer cells.
The PI3K-Akt pathway is a key regulator of cell survival
through multiple downstream targets. The FOXO family of fork-
head transcription factors AFX, FKHR, and FKHRL1 are known
to mediate apoptosis by activating the transcription of proapo-
ptotic genes such as FasL and Bim (Burgering and Medema,
2003). Phosphorylation of the FOXO proteins by Akt results in
their cytoplasmic retention by interaction with 14-3-3 proteins,
thereby sequestering them from their gene targets. Similarly,
Akt can phosphorylate the proapoptotic Bcl-2 family member
Bad, causing its sequestration from the mitochondrial mem-
brane by 14-3-3 proteins (reviewed in Datta et al., 1999). In
addition, under some conditions, Akt can promote cell survival
by indirectly activating the pro-survival transcription factor
nuclear factor-κB (NF-κB) through the phosphorylation of I-κB
kinase (IKK) (Ozes et al., 1999; Romashkova and Makarov,
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1999). Finally, there may exist a reciprocal regulation between
the PI3K-Akt pathway and the tumor suppressor protein p53
(Trotman and Pandolfi, 2003): PTEN is a transcriptional target of
p53, while under some conditions, Akt can promote p53 degra-
dation by phosphorylating and activating its negative regulator
Mdm2 (Mayo and Donner, 2001; Zhou et al., 2001). Evasion
from apoptotic stimuli is a prerequisite for tumor formation.
Using a mouse lymphoma model, it was found that the loss of
p53 circumvents normal apoptotic pathways (reviewed in
Schmitt, 2003). It is likely that for the same reason, hyperactiva-
tion of the PI3K-Akt pathway is selected for in many tumors as a
mechanism of overcoming apoptotic stimuli. This possibility is
supported by the recent finding that PTEN and p53 mutations
are rarely found together in the same breast tumor (Kurose et
al., 2002). A plausible explanation is that the loss of either PTEN
or p53 would reduce the selective pressure for loss of the other
since either mutation would enable unregulated cell survival.
The PI3K-Akt pathway, in parallel to the Ras/MAPK path-
way, contributes to the regulation of cell cycle progression, 
particularly at the G1/S transition.The kinase GSK3 phosphory-
lates and promotes the degradation of cyclin D1 and Myc, two
proteins that drive S phase entry. Akt phosphorylates and
inhibits GSK3, thereby contributing to the stabilization of cyclin
D1 and Myc (Diehl et al., 1998; Sears et al., 2000). The FOXO
transcription factors repress cyclin D1 expression while enhanc-
ing expression of the cell cycle inhibitors p27kip1 and p130Rb2
(reviewed in Burgering and Medema, 2003). Akt-mediated
phosphorylation of the FOXO proteins therefore promotes
cyclin D1 expression and prevents the expression of cell cycle
inhibitors. Although the roles of the FOXO proteins and GSK3 in
human cancer are unclear, tumor cells often show cyclin D1 or
Myc overexpression and/or reduced levels of p27kip1—alter-
ations that confer a proliferative advantage (Barnes and Gillett,
1998; Pelengaris et al., 2002; Sherr and Roberts, 1999). Further
investigation is required to establish a direct correlation
between hyperactivation of the PI3K-Akt pathway and the dys-
regulation of these cell cycle proteins in tumors. For example, a
high percentage of breast tumors are characterized by overex-
pression of the HER2/Neu receptor, an RTK that potently acti-
vates PI3K, by high levels of cyclin D1, a downstream effector of
F O C U S
Figure 1. The PI3K-Akt signaling pathway involved in human cancer
Growth factor RTKs recruit class-Ia PI3K, which is a heterodimer of p85 regulatory subunit and p110 catalytic subunit, through direct interaction or adaptor
molecules. Ras can also recruit PI3K. At the membrane, PI3K phosphorylates PIP2 and converts it to PIP3, which recruits the serine-threonine protein kinases
Akt and PDK1 to the membrane. PDK1 consequently phosphorylates and activates Akt, which in turn regulates a number of downstream targets. Akt pro-
motes cell survival by inhibiting proapoptotic proteins such as Bad, forkhead, and p53, and activating pro-survival proteins such as NF-κB. Akt regulates cell
cycle progression by indirectly stabilizing cyclin D1 and Myc. Akt also stimulates protein synthesis and cell growth by activating the mTOR pathway through
inhibition of the tuberin/hamartin complex. Known oncogenes are colored orange and tumor suppressors green; red flashes indicate promising targets for
therapeutic intervention. Other signaling pathways mediated by class-Ia PI3K (such as glucose homeostasis downstream of the insulin receptor) are omit-
ted for clarity. See text for further details.
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Akt, and/or by the loss of PTEN, a negative regulator of the
PI3K pathway (Barnes and Gillett, 1998; Vivanco and Sawyers,
2002).
Coordination between cell cycle progression and cell
growth (i.e., an increase in cell size) is critical for cell prolifera-
tion. Cell growth is controlled, in large part, through the regula-
tion of protein synthesis, and dysregulation of protein synthesis
is likely to contribute to the abnormally high growth rate
observed in tumor cells (Ruggero and Pandolfi, 2003). In
response to both nutrient availability and mitogenic growth fac-
tors, the mammalian target of rapamycin (mTOR) controls cell
growth by activating the 70 kDa ribosomal S6 kinase (S6K1)
and inhibiting the elongation-initiation factor 4E binding protein-
1 (4E-BP1), two events which stimulate protein translation
(Fingar et al., 2002). In response to growth factors, the PI3K-Akt
pathway activates mTOR, at least in part, through a recently
defined pathway involving Akt’s phosphorylation and inhibition
of the tuberous sclerosis complex-2 (TSC2) gene product
tuberin (reviewed in Manning and Cantley, 2003). Tuberin has
recently been shown by several groups to be a GTPase-activat-
ing protein (e.g., Garami et al., 2003), and therefore inhibitor, of
the Ras-like small G protein Rheb, which is an activator of
mTOR. TSC2 is one of two genes found mutated in the tuberous
sclerosis complex disease (the other one being TSC1, which
encodes the protein hamartin, an obligatory binding partner of
tuberin). The disease is characterized by the formation of
hamartomas in a wide variety of tissues. Interestingly, one of the
most common tumor types in TSC is subependymal giant cell
astrocytomas within the brain, which contain abnormally large
cells of astrocyte origin (Gomez et al., 1999), demonstrating the
contribution of uncontrolled cell growth to the formation of some
tumor types. Furthermore, this PI3K-Akt-TSC-mTOR branch is
emerging as a critical contributor to the oncogenic properties of
the PI3K-Akt pathway (see below; rapamycin suppressing
PTEN tumors).
PI3K may contribute to other aspects of tumorigenesis in
both Akt-dependent and -independent manners. PIP3 regulates
the small GTPase Rac by activating a subset of its GTP-GDP
exchange factors (Welch et al., 2003). Since Rac controls
rearrangement of the actin cytoskeleton and cell motility and is
important for Ras-mediated transformation, PI3K might activate
both Rac- and Ras-dependent invasion events that contribute to
metastasis. In addition, Akt has been reported to phosphorylate
and activate endothelial nitric oxide synthase (eNOS) (Fulton et
al., 1999). As nitric oxide is an important regulator of endothelial
cells and overexpression of eNOS has been associated with
tumors (Xu et al., 2002), the PI3K-Akt pathway may also con-
tribute to tumor angiogenesis.
Mouse cancer models of the PI3K-Akt pathway
Mouse cancer models have been invaluable in understanding
the process of tumorigenesis: they allow defined tests of tumor
genetics, close analysis of tumor pathology, and validation of
therapeutic targets. A number of mouse models have been
established to investigate the role of the PI3K-Akt pathway in
cancer (Vivanco and Sawyers, 2002). Targeted deletion of
PTEN recapitulates many of the ramifications of PTEN loss in
human cancers: mice heterozygous for PTEN develop tumors in
lymphoid, thyroid, breast, endometrial, prostate, and other tis-
sues (e.g., Di Cristofano et al., 1998).Tissue-specific deletion of
PTEN in T cells causes aggressive lymphomas, and mammary
gland deletion of PTEN causes breast tumors (reviewed in
Kishimoto et al., 2003). The consequences of mutating down-
stream components of the PI3K-Akt pathway have also been
examined in mice. For instance, mice heterozygous for TSC2
develop kidney and lung adenomas analogous to those seen in
the human TSC disease (Onda et al., 1999). Interestingly, tis-
sue-specific deletion of either PTEN or TSC1 in the brain results
in similar phenotypes, including larger brain, increased cell size,
and astrogliosis, arguing the importance of cell growth
regulation in the tumorigenesis of this organ (Kishimoto et al.,
2003; Uhlmann et al., 2002). Furthermore, expression of acti-
vated Akt in the murine prostate results in prostate intraepithe-
lial neoplasia with gene expression profiles resembling that of
human prostate cancer, highlighting the role of the PI3K-Akt
pathway in prostatic tumors (Majumder et al., 2003).
Mouse models have been useful in determining the cooper-
ativity among different oncogenes and tumor suppressors. For
example, it has been shown that the expression of either acti-
vated Ras or activated Akt alone is not sufficient to cause
glioblastoma in mice, while their coexpression results in aggres-
sive glioblastoma multiforme (Holland et al., 2000). Furthermore,
mice that are doubly heterozygous for PTEN and p27kip1 devel-
op prostate cancer with 100% penetrance, a phenotype much
more severe than mice heterozygous for either gene alone.
Interestingly, unlike the single heterozygous mice, loss of het-
erozygocity of neither PTEN nor p27kip1 is seen in these
tumors, suggesting that the haploinsufficiency of two tumor sup-
pressors may be sufficient to allow tumor formation (Di
Cristofano et al., 2001). Mouse genetic studies also offer the
opportunity for drug target validation. For example, in mice, loss
of cyclin D1 completely protects against breast tumors elicited
by MMTV-neu overexpression (Yu et al., 2001). Analogously, it
would be interesting to test whether targeted deletion of PI3K or
Akt would protect PTEN heterozygous mice from developing
tumors. It has been shown that deletion of Akt-1 from PTEN−/−
ES cells partially reverses the enhanced cell survival and prolif-
eration phenotype resulting from PTEN deletion (Stiles et al.,
2002). Such genetic analysis would help in verifying drug tar-
gets in tumors with a given genetic lesion.
Finally, mouse tumor models are ideal for evaluating experi-
mental therapeutic agents in vivo. For example, both the PI3K
inhibitor LY294002 and the mTOR inhibitor CCI-779 have been
shown to be effective in vivo at reducing tumor growth in mouse
cancer models (see below). Such in vivo validation is critical in
the preclinical development of candidate drugs.
Therapeutic approaches of targeting the PI3K-Akt pathway
in cancer
Components of the PI3K-Akt pathway present promising targets
for therapeutic intervention for several reasons. First, this path-
way serves to inhibit many “tumor suppressor-like” proteins
such as the FOXO transcription factors, Bad, GSK3, and the
tuberin/hamartin complex that negatively regulate cell survival,
proliferation, and growth. Blocking this pathway could therefore
simultaneously inhibit the proliferation of tumor cells and sensi-
tize them toward apoptosis. Second, many components in the
PI3K-Akt pathway are kinases, one of the most “druggable”
classes of intracellular targets, and are ideal for the develop-
ment of small molecule inhibitors. Third, as hyperactivation of
the PI3K-Akt pathway is found in a wide range of tumors, drugs
inhibiting this pathway are likely to have broad applications for
treating different types of cancer.
Since cancer is a group of heterogeneous diseases, the
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choice of therapeutics thus depends on the particular molecular
signature of a given tumor. Successful identification of tumors
with a hyperactive PI3K-Akt pathway is a prerequisite to the tar-
geting of this pathway. The loss of PTEN can be directly
assessed by either Western blot or immunohistochemistry of
primary tumor samples (McMenamin et al., 1999). The advent
of high-quality phosphospecific antibodies has made it possible
to measure the activation of various components in the PI3K-
Akt pathway in primary tumors. Immunohistochemistry using
antibodies against phosphorylated Akt serine 473, which close-
ly parallels Akt activation, has revealed high levels of Akt phos-
phorylation in aggressive prostate tumors (Malik et al., 2002). It
has also been demonstrated that glioblastomas can be classi-
fied based on their reactivities toward phosphospecific antibod-
ies against various components in the PI3K-Akt pathway (Choe
et al., 2003). This ability to assess signaling in situ is useful for
evaluating the effectiveness of therapeutics, and such feedback
should help physicians to quickly and rationally identify the most
effective treatment.
Inhibitors against RTKs have been an active area of drug
development (Shawver et al., 2002). As hyperactivation of the
PI3K-Akt pathway is critical for tumor cell transformation and
resistance to chemotherapeutic agents (Knuefermann et al.,
2003; Skorski et al., 1997), it is likely that RTK inibitors such as
Herceptin (which blocks the Erb2/HER2 receptor) and Gleevec
(which inhibits the BCR-Abl, c-KIT, and PDGF-R tyrosine kinas-
es) achieve their anti-tumor effects, at least in part, by shutting
off upstream signaling to the PI3K-Akt pathway. The success of
RTK inhibitors, however, could be hampered by activating muta-
tions or gene amplifications affecting downstream signaling
components (such as p85, p110, and Akt) or by the loss of neg-
ative regulators (such as PTEN). Indeed, it has been recently
shown that loss of PTEN in tumor cells can confer resistance to
Iressa (an epidermal growth factor receptor RTK inhibitor) by
setting a high threshold of Akt activation (Bianco et al., 2003).
The most direct approach to inhibit the PI3K-Akt pathway
would be to target PI3K itself (Table 1). The PI3K inhibitors
LY294002 and wortmannin, both targeting the catalytic site of
p110, have been extensively used as research tools. In a mouse
xenograft model of ovarian tumors, LY294002 has been show to
inhibit tumor growth in vivo (Hu et al., 2002). Since the PI3K cat-
alytic domain is highly conserved among PI3K family members,
it is not surprising that neither compound discriminates among
the various isoforms of PI3K. The recent elucidation of the p110
catalytic subunit crystal structure (reviewed in Djordjevic and
Driscoll, 2002) should aid the development of more isoform-
specific inhibitors that will spare other PI3K isoforms (such as
the class-Ib PI3K downstream of G protein-coupled receptors)
and thus affect fewer cellular processes. An alternative and
potentially more selective approach is to block the phosphotyro-
sine binding of the p85 SH2 domains, hence preventing the
recruitment and activation of class-Ia PI3K by RTKs. The p85
SH2 domains recognize a short phosphotyrosine motif (Nolte et
al., 1996), and small peptidomimetics of this motif have been
shown to be effective inhibitors of these SH2 domains (Eaton et
al., 1998). Similarly, inhibitors that disrupt the Ras-p110
interaction may also be useful at blocking PI3K activation
(Djordjevic and Driscoll, 2002).
Kinase inhibitors that target either Akt or PDK1 would also
be effective at turning off this pathway. Due to the high similarity
of the catalytic domains among AGC family kinases (which
include Akt and PDK1), first-generation inhibitors thus far lack
specificity (Davies et al., 2000). High-resolution crystal struc-
tures of the Akt and PDK1 kinase domains should aid in the
development of more selective inhibitors (Komander et al.,
2003; Yang et al., 2002). Another potentially powerful strategy
for inhibiting Akt is to disrupt the binding of its PH domain to
PIP3 (Thomas et al., 2002), thereby preventing its membrane
translocation and activation by PDK1. Novel analogs of the
PIP3 phosphoinositide ring have been shown to be effective Akt
inhibitors in cell culture (Kozikowski et al., 2003). Such inhibitors
are also likely to block other PIP3 binding PH domains such as
the PH domain of PDK1.
Because only a subset of the cellular processes regulated
by the PI3K-Akt pathway are involved in tumorigenesis, the
choice of drug targets must take into account the adverse
effects resulting from the inhibition of other PI3K-Akt-dependent
cellular processes. For example, insulin’s effects on metabolism
are mediated through the PI3K-Akt pathway (Saltiel and Kahn,
2001): inhibitors of PI3K or Akt are therefore likely to perturb
glucose homeostasis. It would be desirable, therefore, to target
components of branches further downstream in the PI3K-Akt
pathway, such as mTOR, Bad, and the FOXO proteins that are
more exclusively involved in cell growth, survival, and prolifera-
tion. For example, the binding of 14-3-3 proteins to phosphory-
lated Bad or the FOXO proteins could potentially be disrupted
by peptidomimetics or small molecules. Such inhibitors would
preserve the activity of these proapoptotic proteins downstream
of Akt, and thus sensitize tumors toward apoptosis.
Recently, much attention has been focused on targeting
mTOR in cancer treatment. Originally discovered as an
immunosuppressant, the mTOR inhibitor rapamycin and its
analogs (such as CCI-779) have been shown to inhibit the pro-
liferation of some tumor cells in vitro, as well as to reduce tumor
growth in vivo in PTEN heterozygous mice and in mice carrying
xenografted human tumors (Neshat et al., 2001; Dudkin et al.,
F O C U S
Table 1. Promising therapeutic targets in the PI3K-Akt pathway
Target Strategy
PI3K The p110 catalytic site inhibitors LY294002 and wortmannin are successful research tools. Agents could also be developed to disrupt
the binding of the p85 SH2 domains to RTKs, or to disrupt Ras-p110 interaction.
Akt and PDK1 UCN-01 is a good PDK1 inhibitor, though it lacks specificity. Novel phosphatidylinositol analogs that disrupt Akt PH domain-PIP3 
interaction are effective at blocking Akt activation. Two other experimental agents, SR13668a and deguelin (Chun et al., 2003) also 
inhibit Akt through as yet undefined mechanisms.
mTOR Several rapamycin analogs such as CCI-779 and RAD001, which specifically inhibit mTOR, are being developed clinically as cancer
therapeutics. 
aDr. L. Jong (ling.jong@sri.com), SRI International, personal communication.
Examples are chosen to illustrate different strategies for drug development, see text for further details. We expect this list of targets to expand significantly in
the near future as several programs aimed at targeting this pathway are underway.
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2001; Podsypanina et al., 2001). Several rapamycin analogs
have already been approved for use in transplant patients as
immunosuppressants (Saunders et al., 2001), and some are
currently in clinical trials as cancer therapeutics (Table 1). Other
components of the PI3K-Akt-TSC-mTOR branch, such as Rheb
and S6K1, may also be exploited as drug targets in the future.
As the PI3K-Akt pathway is involved in the survival, growth,
and proliferation of normal cells, a reasonable therapeutic index
would depend on tumors being more sensitive to inhibitors of
this pathway than normal tissues. The prevalence of a hyperac-
tivated PI3K-Akt pathway in human cancers indicates this may
indeed be the case, and a partial inhibition of this pathway might
be sufficient to inhibit tumor growth while sparing normal cells.
The success of Herceptin and Gleevec serve as encouraging
precedents: in both cases, the therapeutic index is high
because the tumor cells being treated are much more depen-
dent on the activation of the respective signaling pathways than
are normal cells. In addition, maximum efficacy and minimum
side effects might result from combining PI3K-Akt pathway
inhibitors with cancer therapeutics having other mechanisms of
action, as demonstrated in a mouse tumor model with the com-
bination of LY294002 and paclitaxel (Hu et al., 2002). Finally,
tumors of different origin that arise from hyperactivation of the
PI3K-Akt pathway are likely be differentially sensitive to the inhi-
bition of different downstream targets. The effectiveness of tar-
geting a specific branch of this pathway will depend on, for
example, which Akt substrates are phosphorylated in the given
tumor and could also depend on the differentiation state of the
tumor cells. The selective use of different PI3K-Akt pathway
inhibitors based on such knowledge should further improve
their therapeutic index.
Perspective
The last two decades have seen the PI3K-Akt signaling path-
way being firmly established as a critical contributor toward
tumorigenesis. The elucidation of the role of this pathway in cell
growth, survival, and proliferation has shed light on why regula-
tion of this pathway is so often altered within tumors.
Components of the PI3K-Akt pathway have emerged as promis-
ing new targets for the development of cancer therapeutics, and
first-generation inhibitors of this pathway have been shown to
be effective at reducing tumor cell growth both in vitro and in
vivo. The continuing efforts to develop specific, high-affinity
inhibitors against the PI3K-Akt pathway will surely yield new
therapeutics to treat human cancer.
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